Chennai : The Chennai-based Regenix Group, a pharmaceutical and health care company, which is into manufacturing and marketing pharmaceutical, biotech products, medical equipment, first-aid kits, and running a network of pharmacy retail units, is planning to increase its turnover from Rs 25 crore to Rs 67 crore in 2011-12. The group is investing Rs 13 crore for its expansion plans in diagnostics, dentistry and pharmacies.

Talking about the group’s plans for 2011-12, Dr A Ramamurthy, President, Regenix, said that the Regenix group is expanding its diagnostics by setting up a state-of-the-art central lab with the investment of Rs 5 crore. The lab will be inaugurated later part of January, 2011. The company has already set up 10 diagnostic centers across Tamil Nadu. Additionally, 15 more labs will be established by the end of this year. The central lab and peripheral entities are expected to yield revenues of about Rs 5 crore.

Regenix 2011 growth plan includes establishing a chain of dental clinics. The group has launched 4 such centers. As many as 21 more clinics will be set up at a cost of Rs 3 crore in 2011. The expected revenue from dental chain is Rs 3 crore in the first year.

Regenix’s SuperMed, the Rs 10 crore retail pharmacy chain with 14 outlets, is planning to increase the number of outlets to 25 with an additional investment of Rs 2 crore. SuperMed is expected to register a turnover of Rs 20 crore in 2011.

Regenix’s pharmaceutical units: Bhartilife Sciences and Queen, are in the process of launching four new formulations. Currently they have a field force of 100 people and 30 formulations in Tamil Nadu and Andhra Pradesh. Four of its brands crossed Rs 2 crore valuation within 18 months of launch. The current turnover of the pharmaceutical operations is Rs 10 crore.

The company has plans to expand the marketing of pharmaceutical products in Kerala and Karnataka in this year and is proposing to deploy 50 more people to its field force. Regenix’s pharmaceutical operations is aiming to cross the sales figure of Rs 20 crore. In 2011-12, the group will be investing Rs 2 crore for the growth of its pharmaceutical business.

Mur & Mur, the biotech division of Regenix, which is operating in agri as well as healthcare sector, supplies kits to 35 R&D centers and 100 corporate hospitals through 7 major distributors across India. During the new financial year, this division will increase its field force to 25 from current number of 15 and expects its turnover to cross the Rs 3 crore mark. Mur & Mur will also launch two new products during 2011.

Regenix’s medical equipment division is entering into an agreement with Welch Allyn for service contract. The group is investing Rs 1 crore in this unit, to increase the division’s turnover to Rs 10 crore.

The first aid kit, surgical disposables and other export operation of the Livmedica Equipments (LME) Ltd is expected to reach a turnover to Rs 6 crore from current revenue of Rs 2 crore.

Dr Ramamurthy said that the consolidated expansion plan of the group on the back of existing operations will boost its turnover to about Rs 67 crore for 2011-12 .The additional investment of Rs 13 crore for the above plan will be through internal accruals and promoters’ contribution along with bank funding.

Regenix Group expects to register a turnover of Rs. 25 crore for the year ending 2010-11.